AURO LABORATORIES LTD. (AUROLAB)

BSE: ₹256.90
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication

Enclosed herewith Newspaper Advertisement

2026-06-01 17:40:40
Compliances-Reg.24(A)-Annual Secretarial Compliance

Enclosed herewith Annual Secretarial Compliance Report for the Year Ended March 31, 2026.

2026-05-29 21:32:33
Announcement under Regulation 30 (LODR)-Change in Management

Enclosed herewith appointment of Chief Financial Officer, Tax Auditor, Internal Auditor and Reappointment of Cost Auditor.

2026-05-29 20:53:50
Results For The Year Ended March 31, 2026

Enclosed herewith Financial Results for the year ended March 31, 2026

2026-05-29 20:40:08
Board Meeting Outcome for Held On May 29, 2026

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at their meeting held today i.e., May 29, 2026 inter-alia, considered the matters as enclosed herewith.

2026-05-29 20:28:20
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

Auro Laboratories Limited has submitted the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Resignation of Mr. Kuntal Pancholi as the Chief Financial Officer & Key Managerial Personnel of the Company w.e.f May 28, 2026.

2026-05-28 20:01:28
Board Meeting Intimation for Board Meeting To Be Held On May 29, 2026

Audited Financial Results of the Company along with Report of the Auditors for the Quarter and Year Ended March 31, 2026 and any other matter with the permission of the Chair.

2026-05-25 20:38:31
Receipt Of “Certification Of Substances Department” From European Directorate For The Quality Of Medicines & Healthcare (“EDQM”)

Auro Laboratories Limited submits that the Company has received a "Certification of Substances Department" from the European Directorate for the Quality of Medicines & Healthcare ("EDQM") for the Company's Manufacturing facility situated at M.I.D.C Tarapur, Maharashtra.

2026-05-05 19:15:39
Receipt Of “Certificate Of GMP Compliance Of A Manufacturer” From Swissmedic Swiss Agency For Therapeutic Products.

Auro Laboratories Limited submits that the Company has received a 'Certificate of GMP Compliance of a Manufacturer' from Swissmedic Swiss Agency for Therapeutic Products for the Company's manufacturing facility situated at M.I.D.C Tarapur, Maharashtra.

2026-05-05 19:10:10
Announcement under Regulation 30 (LODR)-Credit Rating

Auro Laboratories Limited has submitted the Disclosure in relation to Credit Rating obtained by the Company from Acuite Ratings & Research Limited.

2026-04-14 18:16:07

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 10.18 13.41 17.98 12.06 5.72 3.10 3.05 7.40 2.77 8.84 9.39 9.83
YOY Revenue Growth % -8.96% 6.78% 15.07% -10.81% -43.82% -76.88% -83.01% -38.65% -51.5% 184.95% 207.49% 32.87%
Other Income 0.36 0.32 0.42 0.40 0.20 0.31 0.14 0.13 0.42 0.98 0.18 0.66
Total Income 10.55 13.73 18.40 12.46 5.92 3.41 3.20 7.53 3.19 9.81 9.57 10.50
Total Expenses + 9.57 11.00 14.61 9.61 4.92 2.93 3.13 7.18 3.30 8.09 7.83 8.90
Cost of Materials Consumed 7.20 8.46 7.62 5.76 0.65 -0.08 1.18 3.34 1.25 6.15 3.12 3.73
Employee Benefit Expense 0.84 0.95 1.22 2.13 1.09 1.05 0.03 0.64 0.49 1.45 1.59 2.00
Other Expenses 2.22 2.90 3.02 3.12 1.56 1.27 0.29 0.81 1.35 3.06 2.62 2.47
Operating Profit 0.62 2.41 3.37 2.45 0.80 0.17 -0.07 0.22 -0.52 0.74 1.56 0.94
OPM % 6% 18% 18.7% 20.3% 14% 5.5% -2.4% 3% -18.8% 8.4% 16.6% 9.5%
Profit Before Tax + 0.98 2.73 3.79 2.85 1.01 0.48 0.07 0.35 -0.11 1.72 1.74 1.46
Tax Expense 0.27 0.76 1.05 0.53 0.25 0.12 0.02 -0.04 0.00 1.00 -0.21 0.48
Tax % 27.8% 27.8% 27.8% 18.6% 25.2% 25.2% 25.1% -11.8% - 58.4% -12.3% 33.3%
Profit After Tax 0.71 1.97 2.73 2.32 0.75 0.36 0.05 0.39 -0.11 0.72 1.95 0.97
EPS (Basic) 1.14 3.16 4.39 3.72 1.21 0.57 0.08 0.63 -0.17 1.15 3.13 1.56

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 30.74 19.40 53.64 52.89 50.87 54.25
YOY Revenue Growth % 58.47% -63.83% 1.4% 3.99% -6.24% -
Other Income 2.01 0.66 1.50 0.94 1.09 0.76
Total Income 32.75 20.05 55.14 53.84 51.96 55.01
Total Expenses + 27.80 18.17 44.79 50.39 48.08 44.50
Cost of Materials Consumed 14.28 5.06 29.04 37.30 33.74 27.43
Employee Benefit Expense 5.86 2.47 5.14 4.72 6.24 6.04
Other Expenses 8.81 4.32 11.26 8.08 7.22 8.43
Operating Profit 2.94 1.23 8.84 2.50 2.78 9.75
OPM % 9.6% 6.3% 16.5% 4.7% 5.5% 18%
Profit Before Exceptional 4.95 1.88 10.35 3.45 3.87 10.51
Exceptional Items -0.14 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 4.81 1.88 10.35 3.45 3.87 10.51
Tax Expense 1.28 0.04 2.55 1.00 1.03 3.33
Tax % 26.5% 2.2% 24.7% 29.1% 26.6% 31.7%
Profit After Tax 3.53 1.84 7.79 2.44 2.84 7.18
EPS (Basic) 5.67 2.95 12.50 3.92 4.56 11.52

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 90.32 77.58 54.88 20.33 17.33 13.74
Property, Plant & Equipment 75.18 21.06 22.15 12.62 13.61 13.56
Capital Work in Progress 14.48 56.48 32.68 7.67 3.68 0.13
Non-Current Investments 0.01 0.00 0.05 0.05 0.05 0.00
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.00 0.00 0.00 0.00 0.00 0.05
Current Assets + 30.76 21.51 30.85 35.66 37.63 28.15
Inventories 13.54 3.67 8.24 11.76 4.25 2.55
Trade Receivables 9.15 9.39 13.39 12.40 13.61 7.30
Cash and Cash Equivalents 1.37 0.00 0.99 1.79 5.21 10.82
Current Investments 0.00 0.00 0.00 0.00 0.00 0.00
LIABILITIES & EQUITY
Total Equity 46.35 42.97 41.96 34.20 31.52 28.58
Equity Share Capital 6.23 6.23 6.23 6.23 6.23 6.23
Other Equity 40.12 36.74 35.73 27.97 25.29 22.35
Non-Current Liabilities 46.18 34.49 19.84 3.66 3.31 4.84
Current Liabilities 28.55 21.64 23.93 18.13 20.13 8.47
Total Liabilities 74.74 56.13 43.77 21.79 23.44 13.31

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities 2.11 5.75 18.81 3.28 -6.59 12.82
Cash from Investing Activities -14.78 -24.45 -38.67 -5.08 -5.34 -3.51
Cash from Financing Activities 14.04 17.69 19.09 -8.18 9.79 -0.46
Net Increase/Decrease in Cash 1.37 -1.02 -0.77 -9.98 -2.14 8.85